clopidogrel has been researched along with ST Elevated Myocardial Infarction in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 83 (59.29) | 24.3611 |
| 2020's | 57 (40.71) | 2.80 |
| Authors | Studies |
|---|---|
| Arrot, X; Beygui, F; Bignon, M; Lecoq, G; Malcor, G; Potier, B; Rebouh, I; Roule, V; Roupie, E; Trotel, J | 1 |
| Aguiar, MO; Azevedo, L; Baracioli, LM; Berwanger, O; Chiang, HP; Dalcoquio, TF; de Luca, F; Ferrari, AG; Furtado, RHM; Giugliano, RP; Goodman, S; Lima, FG; Matthias, W; Menezes, FR; Nicolau, JC; Scanavini-Filho, MA | 1 |
| French, JK; Juergens, CP; Kadappu, K; Leung, DY; Lo, S; Mussap, CJ; Nguyen, P; Premawardhana, U; Rajaratnam, R; Xu, J | 1 |
| Chilbert, MR; Denny, O; Mills, K; Woodruff, AE | 1 |
| Andréka, P; Bársony, G; Ferenci, T; Jánosi, A; Szabóné Póth, A; Vajer, P | 1 |
| Arnous, S; Arockiam, S; Coughlan, JJ; Kiernan, TJ; Suleiman, S | 1 |
| Averkov, O; Berwanger, O; Brass, N; Cantor, WJ; Damiani, LP; Dehghani, P; Goodman, SG; Granger, CB; Lavi, S; Lopes, RD; Lutchmedial, S; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Parkhomenko, A; Piegas, LS; Tajer, CD; Tan, M; White, HD | 1 |
| Cao, Z; Dong, S; Guo, S; Liu, G; Shen, J; Sheng, L; Sun, X; Tian, Y; Wu, G | 1 |
| Anastasiou, I; Hamilos, M; Kochiadakis, G; Lazopoulos, G; Pagonidis, K; Petousis, S; Skalidis, E; Vardas, P; Zacharis, E | 1 |
| Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C | 1 |
| Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC | 1 |
| Boytsov, SA; Erlikh, AD; Kukava, NG; Pevsner, DV; Rytova, YK; Shakhnovich, RM; Tereschenko, SN | 1 |
| Li, X; Lv, Q; Wang, Z; Xu, S; Yao, Y | 1 |
| An, L; Lei, M; Li, C; Li, Y; Sun, X; Wang, J; Xue, Z; Yang, Y; Zhao, Z | 1 |
| Charlot, MG; Engstrøm, T; Freeman, P; Glinge, C; Grove, EL; Holmvang, L; Jabbari, R; Jacobsen, MR; Kelbæk, H; Køber, L; Maeng, M; Pedersen, F; Sørensen, R; Torp-Pedersen, C; Veien, K | 1 |
| Aikawa, T; Briasoulis, A; Fujisaki, T; Kampaktsis, PN; Kuno, T; Malik, A; Saito, T; Slipczuk, L; Takagi, H; Wiley, J | 1 |
| Benedetto, U; Doble, B; Harris, J; Hopewell-Kelly, N; Johnson, T; Lasserson, D; Loke, Y; Mahadevan, K; Mumford, A; Pithara, C; Pouwels, KB; Pufulete, M; Redwood, S; Reeves, B; Rogers, C; Sterne, J; Wordsworth, S | 1 |
| Heidari Moghadam, R; Janjani, P; Mahmoudi, S; Nalini, M; Nasiri, S; Rouzbahani, M; Salehi, N; Shojaei, L; Siabani, S; Tadbiri, H | 1 |
| Baas, L; Gawaz, MP; Geisler, T; Gekeler, S; Harm, T; Kreisselmeier, KP; Müller, II; Müller, KAL; Prang, C; Rath, D; Schröder, S | 1 |
| Burgess, SN; Figtree, GA; Graham, MM; Kinnaird, T; Kontopantelis, E; Ludman, P; Mamas, MA; Rashid, M; Sharp, ASP; Shoaib, A | 1 |
| Bessette, LG; Cervone, A; Cheng, S; Glynn, RJ; Kim, DH; Ko, D; Lee, SB; Lin, KJ; Pande, A | 1 |
| Furui, K; Ishii, H; Kanzaki, Y; Komeyama, S; Morishima, I; Morita, Y; Murohara, T; Nagai, H; Shibata, N; Sugiyama, H; Takagi, K; Tanaka, A; Tsuboi, H; Watanabe, N; Yamauchi, R; Yoshida, R; Yoshioka, N | 1 |
| Boivin-Proulx, LA; Costa, F; Marquis-Gravel, G | 1 |
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Boersma, C; Claassens, DMF; de Boer, A; Deneer, VHM; Dewilde, WJM; Hermanides, RS; Herrman, JR; Janssen, PWA; Kelder, JC; Morisco, C; Mosterd, A; Postma, MJ; Ten Berg, JM; Tjon Joe Gin, RM; van 't Hof, AWJ; van der Harst, P; Vos, GJA | 1 |
| Cairns, JA; Cantor, WJ; Džavík, V; Jolly, SS; Kedev, S; Lavi, S; Meeks, B; Moreno, R; Sidhu, RS; Stankovic, G; Welsh, RC; Yuan, F | 1 |
| Kheiri, B; Moreland, JA; Osman, K; Osman, M; Saleem, M; Sengupta, PP; Shigle, AJ | 1 |
| Gaudieri, V; Nappi, C; Petretta, M | 1 |
| Açıkel, S; Aker, M; Algül, E; Çimen, T; Dural, M; Erat, M; Felekoğlu, MA; Guliyev, İ; Sunman, H; Tulmaç, M | 1 |
| Akita, K; Amano, T; Inohara, T; Ishii, H; Kadota, K; Kohsaka, S; Maekawa, Y; Nakamura, M; Numasawa, Y; Yamaji, K | 1 |
| Cao, B; Fu, Q; Gao, C; Jiang, C; Liu, X; Ma, Q; Qu, F; Wei, P | 1 |
| Bolognese, L; Cantor, WJ; Cequier, Á; Chettibi, M; Collet, JP; Diallo, A; Ecollan, P; Fabris, E; Goodman, SG; Hamm, CW; Hammett, CJ; Hermanides, RS; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Merkely, B; Montalescot, G; Silvain, J; Storey, RF; Tavenier, AH; Ten Berg, JM; van 't Hof, AWJ; Vicaut, E; Willems, FF; Zeymer, U | 1 |
| Ma, YT; Xie, X; Xiu, WJ; Yang, HT; Zheng, YY | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Biolè, C; Biondi-Zoccai, G; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; Conrotto, F; Correia, L; D'Ascenzo, F; De Ferrari, GM; Dominguez-Rodriguez, A; Durante, A; Fabrizio, U; Fernández, MC; Fujii, T; Gaido, F; Gallo, D; Garay, A; Gili, S; González-Juanatey, JR; Grosso, A; Henriques, JPS; Huczek, Z; Iñiguez-Romo, A; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Nie, SP; Nuñez-Gil, I; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rettegno, S; Rognoni, A; Song, X; Stone, GW; Taha, S; Templin, C; Valdés, M; Velicki, L; Wilton, SB; Xanthopoulou, I | 1 |
| Bannon, SF; da Costa Lino, DO; de Alcantara Lima, N; de Castro, RL | 1 |
| Achilli, F; Avalli, L; Bozzano, A; Calchera, I; Camisasca, P; Colombo, V; Lettino, M; Maggioni, E; Mauro, A; Montemerlo, E; Righetti, S; Sala, D; Soffici, F | 1 |
| Bainey, KR; Devireddy, C; Gibson, CM; Gopalakrishnan, L; Grip, L; Guo, J; Kazziha, S; Kumar, V; Marshall, JJ; Mavromatis, K; Pinto, D; Singh, P; Stouffer, GA | 1 |
| Gao, L; Geng, L; Guo, W; Li, H; Li, J; Wan, Q; Wang, X; Wang, Y; You, J; Zhang, Q | 1 |
| Claeys, MJ; De Luca, L; Dörler, J; Erne, P; Jukema, JW; Lüscher, TF; Matter, CM; Radovanovic, D; Weidinger, F; Zeymer, U | 1 |
| Ferlini, M; Galvani, M; Visconti, LO | 1 |
| Antonicelli, R; Bongioanni, S; Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Luca, G; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Grosseto, D; Mariani, M; Morici, N; Murena, E; Petronio, AS; Piatti, L; Ravera, A; Rogacka, R; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A; Verdoia, M; Vitrella, G | 1 |
| Belle, L; Berthier, R; Cayla, G; Chevalier, B; Funck, F; Hulot, JS; Khalife, K; Montalescot, G; Piot, C; Tafflet, M | 1 |
| Bergmeijer, TO; Claassens, DMF; Deneer, VHM; Hermanides, RS; Hinrichs, DL; Tavenier, AH; Ten Berg, JM; van 't Hof, AWJ; Vos, GJA | 1 |
| Butala, NM; Faridi, KF; Garratt, KN; Kennedy, KF; Maddox, TM; Secemsky, EA; Yeh, RW | 1 |
| Si, LY; Su, Y; Wang, Z; Xu, Q; Zhou, DY | 1 |
| Ai, G; Gu, C; Han, Y; Hao, Y; Liu, Y; Qiu, M; Wang, X; Xu, P; Yang, X; Zhang, J; Zhang, L; Zhao, D; Zhao, X; Zhou, M | 1 |
| Ahtarovski, KA; Engstrøm, T; Ghotbi, AA; Göransson, C; Høfsten, DE; Kelbæk, H; Kyhl, K; Køber, L; Lønborg, J; Nepper-Christensen, L; Sabbah, M; Sadjadieh, G; Schoos, MM | 1 |
| Al Faraidy, KA; Al-Ali, AK; Al-Mansori, MA; Al-Muhanna, FA; Al-Rubaish, AM; Alali, RA; Alshehri, AM; Asselbergs, FW; Claassens, DMF; Cyrus, C; Khalil, RM; Sulieman, MM; Ten Berg, JM; Vatte, C | 1 |
| Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Yan, H; Zhao, H; Zhou, J; Zhou, P | 1 |
| De Servi, S; Landi, A | 1 |
| Anastasiou, I; Goudevenos, J; Hahalis, G; Hamilos, M; Kanakakis, J; Karvounis, C; Koutouzis, M; Michalis, L; Raisakis, K; Stakos, D; Tsiafoutis, I; Vardas, P; Vasilikos, V | 1 |
| Atmaca, Y; Erol, Ç; Esenboga, K; Göksülük, H; Ozyuncu, N; Tan, TS | 1 |
| He, H; Zhou, T | 1 |
| Huang, Z; Lin, Y; Su, H; Wang, N; Zhang, M | 1 |
| Banhegyi, G; Becker, D; Domokos, D; Edes, IF; Hizoh, I; Kiss, RG; Major, L; Merkely, B; Ruzsa, Z; Szabo, A | 1 |
| Corbett, SJ; Ftouh, S; Lewis, S; Lovibond, K | 1 |
| Aziz Alkatiri, A; Firdaus, I; Giantini, A; Gilang Rejeki, V; Hoetama, E; Listiyaningsih, E; Sukmawan, R; Suridanda Danny, S | 1 |
| Beasley, M; Brown, TM; Cai, A; Clarkson, SA; Dillon, C; Heindl, B; Limdi, N | 1 |
| Figatowski, T; Gasecka, A; Jaguszewski, MJ; Pruc, M; Ruetzler, K; Szarpak, L | 1 |
| Chen, X; Cui, H; Li, X; Liu, Y; Su, J; Wu, N; Xia, Y; Yang, J; Yao, Q; Zhang, Y; Zhou, Y | 1 |
| Eskola, M; Hautamäki, M; Hernesniemi, J; Lehtimäki, T; Lyytikäinen, LP; Nikus, K; Oksala, N; Tynkkynen, J | 1 |
| Gao, R; Gao, Z; Liu, L; Qiao, S; Tang, X; Wang, Z; Yang, J; Yang, Y; Yuan, J; Zhao, X | 1 |
| Flahive, J; Fraielli, K; Gill, K; Servati, N | 1 |
| Butt, JH; Engstrøm, T; Fosbøl, EL; Gislason, G; Glinge, C; Holmvang, L; Jabbari, R; Jacobsen, MR; Køber, L; Pedersen, F; Sørensen, R; Torp-Pedersen, C | 1 |
| Bainey, KR; Leung, R; Shavadia, JS; Tyrrell, BD; Welsh, RC; Zheng, Y | 1 |
| Boasi, V; Cattunar, S; Mascelli, G; Perri, D; Pistis, G; Sànchez, FA; Secco, GG; Tacchi, C; Vercellino, M | 1 |
| Jang, HJ; Kang, WC; Kim, TH; Kwon, SW; Lee, K; Moon, J; Oh, PC; Park, HW; Park, SD; Suh, J | 1 |
| Armstrong, PW; Gershlick, A; Halvorsen, S; Huber, K; Shavadia, J; Steg, PG; Van de Werf, F; Welsh, R; Zheng, Y | 1 |
| Chiswell, K; Doll, JA; Kosiborod, M; Li, S; Roe, MT; Scirica, BM; Wang, TY | 1 |
| Aitmokhtar, O; Azaza, A; Azzouz, A; Benamara, S; Benathmane, T; Benkhedda, S; Bonello, L; Bouzid, A; Hamza, O; Harbi, F; Kara, M; Monsuez, JJ; Paganelli, F; Saidane, M; Seddiki, S; Sik, A | 1 |
| Arous, S; Bentaoune, T; El Ghali Benouna, M; Habbal, R; Haboub, M | 1 |
| Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
| Adawi, S; Bardicef, M; Gutterman, E; Rubinshtein, R; Shiran, A | 1 |
| C, K; Durgaprasad, R; Erathi, HV; Kanavath, SN; Pvgk, S; Rodda, M; Velam, V | 1 |
| Candela Sánchez, E; Carrillo Alemán, L; Esteve-Pastor, MA; Lozano, T; MacíasVillanego, MJ; Marín, F; Orenes-Piñero, E; PerniasEscrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruíz-Nodar, JM; Sandín Rollán, M; Tello-Montoliu, A; Valdés, M; Véliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Chen, SB; Ji, WJ; Li, YM; Liu, JX; Liu, XL; Lu, RY; Ma, YQ; Sun, J; Yang, GH; Zhang, YY; Zhao, JH; Zhou, X | 1 |
| Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Zimmermann, RH | 1 |
| Chai, HT; Chang, HW; Chen, CJ; Chen, KH; Chua, S; Chung, SY; Lee, WC; Liu, CF; Sung, PH; Tong, MS; Yip, HK | 1 |
| Brener, SJ; Dangas, GD; Deliargyris, EN; Généreux, P; Giustino, G; Kirtane, AJ; Mehran, R; Pocock, SJ; Prats, J; Redfors, B; Stone, GW | 1 |
| Baker, BA; Effron, MB; Fonarow, GC; Henry, TD; McCoy, LA; Peterson, ED; Wang, TY; Zettler, ME | 1 |
| Dudek, D; Dziewierz, A; Kleczyński, P; Plens, K; Rakowski, T; Siudak, Z | 1 |
| Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S | 1 |
| Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Pon, Q; Yang, A; Zimmermann, RH | 1 |
| Alves, CMR; Berwanger, O; Bianco, HT; Caixeta, A; Carvalho, ACC; Damiani, LP; Fonseca, FAH; Fonseca, HA; França, CN; Izar, MC; Klassen, A; Maugeri, IML; Moreira, FT; Pinto, IM; Soriano Lopes, A; Szarf, G; Tavares, MFM | 1 |
| Antonijevic, N; Kusic-Tisma, J; Matic, D; Novkovic, M; Radojkovic, D; Rakicevic, L | 1 |
| Baumbach, A; Byrne, J; Curzen, N; de Belder, MA; Hildick-Smith, DJR; Kinnaird, T; Ludman, P; Mamas, MA; Olier, I; Rashid, M; Sirker, A | 1 |
| Harrington, RA; Yancy, CW | 1 |
| Gach, O; Lancellotti, P; Magne, J; Nyssen, A; Oury, C; Pirlet, C | 1 |
| Berti, S; Bolognese, L; D'Ascenzo, F; De Luca, L; De Servi, S; Gallo, P; Granatelli, A; Gulizia, MM; Musumeci, G; Pennacchi, M; Rigattieri, S | 1 |
| Alexopoulos, D; Bona, RD; Bongo, AS; Capodanno, D; Gaudio, G; Guasti, L; Lupi, A; Meliga, E; Porto, I; Schaffer, A; Valgimigli, M | 1 |
| Chan, KA; Lai, CL; Lai, HY; Lai, MS; Lin, TT; Yang, YY | 1 |
| Nijjer, SS | 1 |
| Adams, H; Ashokkumar, S; Burns, AT; Judkins, C; La Gerche, A; Layland, J; MacIsaac, AI; Palmer, S; Whitbourn, RJ; Williams, PD; Wilson, AM | 1 |
| Guo, S; Li, W; Li, Z; Pan, W; Sun, X; Sun, Y; Wang, L; Wang, S | 1 |
| Averkov, O; Berwanger, O; Candido, CT; Carvalho, AC; Damiani, LP; de Barros E Silva, PGM; Fonseca, F; Goodman, S; Granger, CB; Guimaraes, HP; Jiang, L; Kerr Saraiva, JF; Lasagno, CMR; Lopes, RD; Malaga, G; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Tajer, C; Valeis, N; White, H | 1 |
| Abdalla, A; Ahmed, S; Bachuwa, G; Barbarawi, M; Bhatt, DL; Hassan, M; Haykal, T; Hicks, M; Kheiri, B; Osman, M; Zayed, Y | 1 |
| Dai, W; Li, L; Su, Q; Ye, Z | 1 |
| Fan, CJ; Hu, HY; Li, XY; Su, GH; Wang, GX | 1 |
| Diefenbronn, M; Laghlam, D; Picard, F; Varenne, O | 1 |
| Endo, T; Hanada, K; Higuma, T; Nishizaki, F; Okumura, K; Tomita, H; Yamada, M; Yokota, T; Yokoyama, H | 1 |
| Apostolovic, S; Konstantinovic, SS; Lilic, J; Marinkovic, V; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB | 1 |
| Geng, XY; Ma, JG; Wei, YY; Yu, HR | 1 |
| Hou, J; Jiang, Z; Liu, Q; Sun, M; Wang, S; Wang, W; Wang, Y; Yu, B; Zhang, H; Zhang, R; Zhao, Q | 1 |
| Demir, AR; Karabag, T; Karakurt, H; Karakurt, ST; Somuncu, MU | 1 |
| Bai, S; Chen, T; Du, R; Li, Q; Li, R; Li, X; Liu, H; Liu, J; Wang, L; Wang, X; Wu, H; Zhang, L | 1 |
| Candela-Sanchez, E; Carrillo-Aleman, L; Esteve-Pastor, MA; Lozano, T; Macías, M; Marín, F; Martínez-Martínez, JG; Orenes-Piñero, E; Pernias-Escrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Sandín-Rollan, M; Veliz, A; Vicente-Ibarra, N | 1 |
| Albertsson, P; Angerås, O; Dworeck, C; Erlinge, D; Haraldsson, I; Ioanes, D; Koul, S; Odenstedt, J; Omerovic, E; Persson, J; Petursson, P; Råmunddal, T; Redfors, B; Völz, S | 1 |
| Averkov, O; Berwanger, O; Damiani, LP; de Barros E Silva, PGM; Fonseca, FA; Goodman, SG; Granger, CB; Guimaraes, HP; Jiang, L; Lopes, RD; Malaga, G; Miranda, TA; Moia, DDF; Nicholls, SJ; Nicolau, JC; Paisani, DM; Parkhomenko, A; Piegas, LS; Santos, RHN; Saraiva, JFK; Tajer, C; Valeis, N; White, HD | 1 |
| Baber, U; Baker, BA; Chandiramani, R; Chandrasekhar, J; Claessen, BE; Dangas, G; DeFranco, A; Effron, MB; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Li, SX; Mehran, R; Muhlestein, B; Pocock, S; Rao, SV; Sartori, S; Strauss, C; Toma, C; Weiss, S | 1 |
| Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B | 1 |
| Brust, K; Garncarek, M; Jagas, J; Roleder, T; Witkiewicz, W | 1 |
| Hengstenberg, C; Siller-Matula, JM | 1 |
| Al Shaikh, L; Castle, N; Howard, I; Owen, R | 1 |
| Bruno, V; Egger, F; Farhan, S; Freynhofer, MK; Geppert, A; Huber, K; Hübl, W; Rohla, M; Tscharre, M; Weiss, TW; Willheim, M; Wojta, J | 1 |
| Arad, J; Gilutz, H; Lerman, TT; Reitblat, O; Shimony, A; Zahger, D | 1 |
| Généreux, P; Kirtane, AJ; Madhavan, MV; Mehran, R; Stone, GW; Witzenbichler, B; Xu, K | 1 |
| Kesavamoorthy, B; Virmani, R; Yahagi, K | 1 |
| Croce, KJ; Falcão, FC; Falcão, JL; Lemos, PA; Medeiros, F; Mont'Alverne-Filho, JR; Nicolau, JC; Rodrigues-Sobrinho, CR; Serruys, PW; Silva, RC; Valgimigli, M | 1 |
| Bernat, I; Dragounová, E; Hromádka, M; Jirouš, Š; Pechman, V; Rokyta, R; Seidlerová, J; Tůmová, P | 1 |
| Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P | 1 |
| Benezet, JF; Cayla, G; Cornillet, L; de La Coussaye, JE; Fabbro-Peray, P; Lattuca, B; Leclercq, F; Ledermann, B; Macia, JC; Messner-Pellenc, P; Schmutz, L | 1 |
| Hu, S; Jiang, LX; Li, J; Li, X; Yan, XF; Yu, Y | 1 |
| Baber, U; Berger, PB; Currier, J; Dave, RH; Henry, TD; Mehran, R; Nayyar, P; Rafique, AM; Tobis, J; Wang, TY | 1 |
| Alyasin, N | 1 |
| Araszkiewicz, A; Bartela, E; Grajek, S; Janus, M; Jeremicz, I; Prech, M; Pyda, M; Urbanska, L | 1 |
| Dudek, D; Dziewierz, A; Rakowski, T; Sawina, A; Siudak, Z | 1 |
| Blackman, D; Curzen, N; Dalby, M; Flather, M; Gershlick, AH; Greenwood, JP; Hetherington, S; Kelly, DJ; Khan, JN; Lai, FY; McCann, GP; Nazir, SA; Peebles, C; Swanton, H; Wong, J | 1 |
| Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S | 1 |
| Cattabiani, MA; Di Vito, L; Gatto, L; Limbruno, U; Marco, V; Micari, A; Pawlowski, T; Prati, F; Romagnoli, E; Trivisonno, A; Versaci, F | 1 |
| Bolek, T; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J | 1 |
| Flaherty, JD; Gajjar, M; Ricciardi, MJ; Schimmel, DR; Yadlapati, A | 1 |
| Baek, YS; Kim, DH; Kwan, J; Kwon, SW; Lee, MJ; Park, KS; Park, SD; Shin, SH; Woo, SI | 1 |
| Ebina, T; Hibi, K; Ichikawa, S; Iwahashi, N; Kimura, K; Kimura, Y; Kosuge, M; Maejima, N; Matsuzawa, Y; Minamimoto, Y; Tsukahara, K | 1 |
| Fenstad, ER; Janish, CD; Liang, JJ; Sinak, LJ | 1 |
| Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M | 1 |
| Cheema, AN; Cieza, T; Dehghani, P; Déry, JP; Fisher, HN; Goodman, SG; Henderson, MA; Kokis, A; Lavi, S; Lutchmedial, S; Mehta, SR; Siega, AJ; Welsh, RC; Wong, BY; Zhang, X; Zhu, YE | 1 |
| Baber, U; Clemmensen, P; Dangas, GD; Feit, F; Gersh, BJ; Guagliumi, G; Mehran, R; Ohman, EM; Pocock, SJ; Schoos, MM; Stone, GW; Witzenbichler, B; Yu, J | 1 |
| Barbato, E; Bartunek, J; Ciccarelli, G; Cimmino, G; De Bruyne, B; Di Girolamo, D; Di Serafino, L; Golino, M; Golino, P; Wijns, W | 1 |
| Ahn, JH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, KH; Koh, JS; Kwak, CH; Park, HW; Park, JR; Park, KS; Park, Y; Tantry, US | 1 |
| Benzeroual, D; Elharda, CA; Hattaoui, ME; Oualim, S | 1 |
| Blankenberg, S; Brieger, D; Chen, JY; Goodman, SG; Granger, CB; Grieve, R; Maguire, A; Nicolau, JC; Pocock, SJ; Requena, G; Simon, T; Vega, AM; Yasuda, S | 1 |
7 review(s) available for clopidogrel and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Strategy of dual antiplatelet therapy for patients with ST-elevation myocardial infarction and non-ST-elevation acute coronary syndromes: A systematic review and network meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
Ticagrelor after pharmacological thrombolysis in patients with ST-segment elevation myocardial infarctions: insight from a trial sequential analysis.
Topics: Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor | 2019 |
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Topics: Aged; Aged, 80 and over; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.
Topics: Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Stroke; Survival Analysis; Thrombolytic Therapy; Ticagrelor | 2018 |
Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-anal
Topics: Clopidogrel; Humans; Observational Studies as Topic; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Ticagrelor | 2018 |
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Topics: Adenosine; Antithrombins; Bayes Theorem; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Evidence-Based Medicine; Hirudins; Humans; Markov Chains; Monte Carlo Method; Network Meta-Analysis; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recombinant Proteins; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Contemporary management of ST-segment elevation myocardial infarction.
Topics: Analgesics; Clopidogrel; Humans; Morphine; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
34 trial(s) available for clopidogrel and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction.
Topics: Adenosine Diphosphate; Clopidogrel; Humans; Microcirculation; Myocardial Infarction; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2022 |
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial.
Topics: Clopidogrel; Hemorrhage; Humans; Morphine; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor versus clopidogrel in reducing inflammatory cell infiltration of thrombus aspirated in patients with ST-elevation myocardial infarction.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
Assessment of myocardial salvage in patients with STEMI undergoing thrombolysis: ticagrelor versus clopidogrel.
Topics: Clopidogrel; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Stroke Volume; Thrombolytic Therapy; Ticagrelor; Ventricular Function, Left | 2022 |
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
A Genotype-Guided Strategy for Oral P2Y
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Single-Blind Method; ST Elevation Myocardial Infarction; Stents; Ticagrelor | 2019 |
Short-term efficacy of ticagrelor in acute ST-segment elevation myocardial infarction patients undergoing an emergency percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial.
Topics: Aged; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; ST Elevation Myocardial Infarction; Survival Analysis; Thrombosis; Ticagrelor; Treatment Outcome | 2020 |
Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49).
Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Feasibility Studies; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Tenecteplase | 2020 |
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Drug Substitution; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Cause of Death; Clopidogrel; Comorbidity; Female; Frail Elderly; Geriatric Assessment; Hemorrhage; Humans; Italy; Male; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2020 |
Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Topics: Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Humans; Multicenter Studies as Topic; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Point-of-Care Testing; Polymorphism, Genetic; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Saudi Arabia; ST Elevation Myocardial Infarction; Stents; Ticagrelor; Treatment Outcome | 2020 |
Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial.
Topics: Aged; Clopidogrel; Fibrinolysis; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2021 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Discordance Between VASP Phosphorylation and Platelet Aggregation in Defining High On-Clopidogrel Platelet Reactivity After ST-Segment Elevation Myocardial Infarction.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Smoking; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors | 2018 |
Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
Topics: Adenosine; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Preoperative Care; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI.
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk Assessment; ST Elevation Myocardial Infarction; Stents; Ticlopidine; Time Factors; United States | 2017 |
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Recurrence; Risk Factors; Smoking; ST Elevation Myocardial Infarction; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.
Topics: Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2018 |
Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute My
Topics: Adenosine; Anti-Inflammatory Agents; B-Lymphocytes; Biomarkers; Brazil; Clinical Protocols; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Enzyme-Linked Immunospot Assay; Ezetimibe; Female; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Magnetic Resonance Imaging; Male; Metabolomics; Platelet Aggregation Inhibitors; Proteomics; Research Design; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction; Stroke Volume; T-Lymphocytes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
Topics: Adult; Aged; Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Single-Blind Method; ST Elevation Myocardial Infarction; Ticagrelor | 2018 |
Switching from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction undergoing successful percutaneous coronary intervention in real-world China: Occurrences, reasons, and long-term clinical outcomes.
Topics: Aged; China; Clopidogrel; Coronary Thrombosis; Drug Costs; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Beneficial effects of combined administration of Clopidogrel and Aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction: A comparative study.
Topics: Aged; Aspirin; Clopidogrel; Cytokines; Drug Therapy, Combination; Female; Heart; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; ST Elevation Myocardial Infarction; Ticlopidine; Treatment Outcome | 2018 |
Beneficial effect of ticagrelor on microvascular perfusion in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Circulation; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Progression-Free Survival; Recovery of Function; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Time Factors; Ventricular Function, Left | 2019 |
Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial.
Topics: Aged; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Long-Term Care; Male; Middle Aged; ST Elevation Myocardial Infarction; Survival Analysis; Thrombolytic Therapy; Ticagrelor; Treatment Outcome | 2019 |
Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial.
Topics: Aged; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Postoperative Complications; Prospective Studies; Recombinant Proteins; Secondary Prevention; ST Elevation Myocardial Infarction; Survival Rate; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2017 |
Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study.
Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Brazil; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Emergency Medical Services; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; ST Elevation Myocardial Infarction; Thrombectomy; Ticagrelor; Ticlopidine; Time Factors; Time-to-Treatment; Treatment Outcome | 2016 |
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule; Female; Humans; Magnetic Resonance Angiography; Male; Microvessels; Middle Aged; Myocardial Revascularization; Organ Size; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
Topics: Abciximab; Adenosine; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Thrombectomy; Thrombosis; Ticagrelor; Ticlopidine; Tomography, Optical Coherence | 2016 |
Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial).
Topics: Adenosine; Aged; Clopidogrel; Creatine Kinase; Echocardiography; Female; Humans; Male; Microvessels; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Severity of Illness Index; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Vascular Resistance | 2016 |
Pharmacodynamic Assessment of Platelet Reactivity After a Loading Dose of Prasugrel or Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticlopidine | 2016 |
Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes.
Topics: Aged; Antineoplastic Agents, Phytogenic; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Europe; Female; Follow-Up Studies; Heparin; Hospital Mortality; Humans; Incidence; Intraoperative Complications; Male; Middle Aged; New South Wales; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Sex Distribution; Sex Factors; ST Elevation Myocardial Infarction; Survival Rate; Thromboembolism; Ticlopidine; Time Factors; United States | 2016 |
99 other study(ies) available for clopidogrel and ST Elevated Myocardial Infarction
| Article | Year |
|---|---|
Effectiveness and Safety of P2Y12 Inhibitors Pretreatment in Primary Percutaneous Coronary Intervention with Long Transfer Times.
Topics: Aged; Clopidogrel; Female; Hemorrhage; Humans; Percutaneous Coronary Intervention; Registries; ST Elevation Myocardial Infarction | 2022 |
Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Practice of antiplatelet therapy in acute myocardial infarction
Topics: Clopidogrel; Humans; Hungary; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Pre-Percutaneous Coronary Intervention TIMI Flow Grade in STEMI Patients Treated with Pre-Hospital Ticagrelor Loading.
Topics: Clopidogrel; Hospitals; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Features of antiplatelet therapy with P2Y12 receptor inhibitors in patients with myocardial infarction according to the Russian Register of Acute Myocardial Infarction REGION-MI.
Topics: Anticoagulants; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study.
Topics: Adenosine; Aspirin; Clopidogrel; Fibrinogen; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2023 |
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study.
Topics: Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2023 |
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2023 |
Determinants of Left Ventricular Systolic Function One Year after Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction in a Middle-Income Country.
Topics: Aged; Clopidogrel; Creatinine; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; ST Elevation Myocardial Infarction; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2023 |
Thrombus architecture is influenced by the antiplatelet loading treatment in patients with acute myocardial infarction.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; RNA; ST Elevation Myocardial Infarction; Thrombosis; Treatment Outcome | 2023 |
Sex-Specific Differences in Potent P2Y
Topics: Clopidogrel; Female; Humans; Male; Prasugrel Hydrochloride; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2023 |
Utilization of P2Y
Topics: Aged; Clopidogrel; Female; Frailty; Humans; Male; Medicare; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome; United States | 2023 |
Myocardial salvage after ST-segment-elevation myocardial infarction: comparison between prasugrel and clopidogrel in the presence or absence of high-residual platelet reactivity.
Topics: Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction; Tomography, Emission-Computed, Single-Photon | 2021 |
"Ticagrelor or Prasugrel, Doctor?" The Basis for Decision in Clinical Practice.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
Topics: Aged; Clopidogrel; Combined Modality Therapy; Female; Humans; Male; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2019 |
Radionuclide imaging of jeopardized myocardium: From the beginning of the race to the finish line.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Tomography, Emission-Computed, Single-Photon | 2021 |
Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel
Topics: Acute Coronary Syndrome; Atrial Fibrillation; Clopidogrel; Cross-Sectional Studies; Echocardiography, Doppler; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Thrombosis; Databases, Factual; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Incidence; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Prospective Studies; Registries; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2020 |
Delayed PCI 12 Hours after the Onset of Symptoms Is Associated with Improved Outcomes for Patients with ST-Segment Elevation Myocardial Infarction: A Real-World Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; ST Elevation Myocardial Infarction; Time-to-Treatment; Young Adult | 2019 |
Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Recurrence; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors | 2020 |
Concealed Wolff-Parkinson-White Syndrome revealed by acute coronary syndrome.
Topics: Acute Coronary Syndrome; Analgesics, Opioid; Aspirin; Clopidogrel; Drug-Eluting Stents; Electrocardiography; Fibrinolytic Agents; Humans; Male; Middle Aged; Morphine; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Wolff-Parkinson-White Syndrome | 2020 |
Outcomes Related to Antiplatelet Therapy in a High-Risk ST-Segment Elevation Myocardial Infarction Population: A Retrospective Real-World Analysis of an Italian ECMO Center.
Topics: Aged; Aged, 80 and over; Clopidogrel; Extracorporeal Membrane Oxygenation; Female; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries.
Topics: Clopidogrel; Europe; Humans; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor | 2021 |
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?]
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clinical Trials, Phase IV as Topic; Clopidogrel; Hemorrhage; Humans; Multicenter Studies as Topic; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
Topics: Aged; Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Resistance; Female; France; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2020 |
Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI.
Topics: Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Drug Substitution; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Topics: Aged; Cardiologists; Cardiology Service, Hospital; Clopidogrel; Drug Utilization; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome; United States | 2020 |
Efficacy of clopidogrel and ticagrelor under NT-proBNP in hospitalized ST-elevation acute coronary syndrome patients on percutaneous coronary intervention: CCC-ACS Project Analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome; Ventricular Function, Left | 2020 |
Infarct size following loading with Ticagrelor/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction.
Topics: Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
Ticagrelor versus clopidogrel in patients with ST-elevation myocardial infarction: postdischarge mild bleeding and its clinical impacts.
Topics: Aged; China; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Prospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2021 |
Time-dependent impact of Ticagrelor and Prasugrel on infarct size: Looking beyond antiplatelet effect.
Topics: Clopidogrel; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2020 |
Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor?
Topics: Angioplasty; Clopidogrel; Echocardiography; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; ST Elevation Myocardial Infarction; Ticagrelor; Troponin | 2020 |
Early usage of antiplatelet in ST-segment elevation myocardial infarction.
Topics: Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor | 2021 |
Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic.
Topics: Aged; Aspirin; Clopidogrel; Coronavirus Infections; COVID-19; Female; Fibrinolysis; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Reperfusion; Pandemics; Percutaneous Coronary Intervention; Pneumonia, Viral; Recombinant Proteins; ST Elevation Myocardial Infarction; Stents; Survival Analysis; Treatment Outcome; Urokinase-Type Plasminogen Activator | 2020 |
Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.
Topics: Aged; Analgesics, Opioid; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morphine; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Treatment Outcome | 2021 |
Acute coronary syndromes: summary of updated NICE guidance.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Cardiac Rehabilitation; Clopidogrel; Combined Modality Therapy; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Secondary Prevention; ST Elevation Myocardial Infarction; Ticagrelor; United Kingdom | 2021 |
Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
Topics: Adult; Clopidogrel; Cytochrome P-450 CYP2C19; DNA Methylation; Drug Resistance; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Recurrence; Secondary Prevention; ST Elevation Myocardial Infarction; Thrombolytic Therapy | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome | 2021 |
Efficacy and safety of prasugrel and clopidogrel in st-segment elevation myocardial infarction in prehospital setting.
Topics: Acute Coronary Syndrome; Clopidogrel; Emergency Medical Services; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Treatment Outcome | 2022 |
MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction.
Topics: Blood Platelets; Clopidogrel; Humans; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Treatment Outcome | 2021 |
Prehospital Adenosine Diphosphate Receptor Blocker Use, Culprit Artery Flow, and Mortality in STEMI: The MADDEC Study.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Vessels; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Survival Rate; Ticagrelor | 2021 |
Evidence-based oral antiplatelet therapy among hospitalized Chinese patients with acute myocardial infarction: results from the Chinese acute myocardial infarction registry.
Topics: Administration, Oral; Aged; Aspirin; China; Clopidogrel; Drug Utilization; Dual Anti-Platelet Therapy; Evidence-Based Medicine; Female; Healthcare Disparities; Hospitalization; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2021 |
Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Massachusetts; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Stroke; Ticagrelor | 2021 |
Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction.
Topics: Aftercare; Aged; Clopidogrel; Female; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in ST-segment elevation myocardial infarction.
Topics: Clopidogrel; Drug Substitution; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis.
Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Hospital Mortality; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; ST Elevation Myocardial Infarction; Survival Rate; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; ST Elevation Myocardial Infarction; Tetrazoles; Ticlopidine | 2017 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; Femoral Artery; Fibrinolytic Agents; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Mortality; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Radial Artery; Recurrence; Shock; ST Elevation Myocardial Infarction; Tenecteplase; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator | 2016 |
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction | 2018 |
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Resistance; Female; Humans; Male; Microcirculation; Middle Aged; Multivariate Analysis; No-Reflow Phenomenon; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; ROC Curve; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports.
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Ischemic Attack, Transient; Male; Middle Aged; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Stents; Stroke; Tenecteplase; Ticlopidine; Tissue Plasminogen Activator; Treatment Outcome | 2017 |
Non-invasive management of post-partum spontaneous left main coronary artery dissection using cardiac computed tomography angiography.
Topics: Adult; Aspirin; Bisoprolol; Cesarean Section; Clopidogrel; Computed Tomography Angiography; Conservative Treatment; Coronary Angiography; Coronary Vessel Anomalies; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Postpartum Period; Pregnancy; ST Elevation Myocardial Infarction; Ticlopidine; Treatment Outcome; Troponin T; Vascular Diseases | 2017 |
Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI.
Topics: Adult; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymerase Chain Reaction; Polymorphism, Genetic; Prospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors | 2018 |
Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
Impact of Double Loading Regimen of Clopidogrel on Final Angiographic Results, Incidence of Upper Gastrointestinal Bleeding and Clinical Outcomes in Patients with STEMI Undergoing Primary Coronary Intervention.
Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Graft Occlusion, Vascular; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Survival Rate; Taiwan; Thrombolytic Therapy; Ticlopidine; Time Factors | 2017 |
The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study.
Topics: Aged; Clopidogrel; Community Health Services; Female; Hemorrhage; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome; United States | 2018 |
Contemporary use of P2Y
Topics: Adenosine; Adult; Aged; Clopidogrel; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Poland; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition to Disease; Haplotypes; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Factors; Serbia; ST Elevation Myocardial Infarction; Ticlopidine; Treatment Outcome | 2018 |
Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Survival Rate; Ticagrelor; United Kingdom | 2018 |
The TREAT Trial-Moving ST-Elevation Myocardial Infarction Care Forward, With More to Do.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor | 2018 |
Pretreatment with P2Y12 inhibitors and outcome in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Topics: Aged; Belgium; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Survival Analysis; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
[Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Fibrinolytic Agents; Humans; Italy; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug-Eluting Stents; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2018 |
Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction.
Topics: Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Taiwan; Ticlopidine; Time Factors; Treatment Outcome | 2018 |
Clinical outcomes of potent antiplatelets compared with clopidogrel in ST elevation myocardial infarction.
Topics: Clopidogrel; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Ticlopidine | 2018 |
Measurement of microvascular function in patients presenting with thrombolysis for ST elevation myocardial infarction, and PCI for non-ST elevation myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Circulation; Coronary Vessels; Echocardiography; Female; Heart Ventricles; Humans; Male; Microcirculation; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Treatment Outcome; Vascular Resistance; Ventricular Function, Left | 2018 |
Comparison of Ticagrelor with Clopidogrel in Reducing Interleukin-17 and Myeloperoxidase Expression in Thrombus and Improving Postprocedural Coronary Flow in ST-segment Elevation Myocardial Infarction Patients.
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Circulation; Female; Humans; Interleukin-17; Middle Aged; Peroxidase; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Young Adult | 2018 |
[Demographic evolution, clinical characteristics and in-hospital outcomes of older adults treated by primary angioplasty for ST-segment elevation myocardial infarction].
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Female; France; Hospital Mortality; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; ST Elevation Myocardial Infarction; Stroke Volume; Time-to-Treatment | 2019 |
Prasugrel versus clopidogrel for residual thrombus burden in patients with ST-segment elevation myocardial infarction: an optical coherence tomography study.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Retrospective Studies; ST Elevation Myocardial Infarction; Stents; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2018 |
The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Chest Pain; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; ST Elevation Myocardial Infarction; Ticlopidine; Treatment Outcome | 2018 |
Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
Topics: Biomarkers; C-Reactive Protein; Clopidogrel; Female; Humans; Interleukin-1beta; Interleukins; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2018 |
Long Term Cardiovascular Outcome Based on Aspirin and Clopidogrel Responsiveness Status in Young ST-Elevated Myocardial Infarction Patients.
Topics: Adult; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2019 |
Switching of Oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
Topics: Aged; Aged, 80 and over; Angioplasty; Clopidogrel; Coronary Angiography; Female; Hemorrhage; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Stents; Survival Rate; Sweden; Thrombosis; Ticagrelor | 2019 |
Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Prasugrel Hydrochloride; Registries; Retrospective Studies; ST Elevation Myocardial Infarction; Treatment Outcome; United States | 2019 |
The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction.
Topics: Aged; Anterior Wall Myocardial Infarction; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Echocardiography; Female; Follow-Up Studies; Heart Diseases; Heart Ventricles; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Treatment Outcome; Turkey | 2019 |
Replacement of ticagrelor with clopidogrel complicated with acute in‑stent thrombosis.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stents; Thrombosis; Ticagrelor | 2019 |
Shedding Light on Long-Term Effects of Early Antiplatelet Strategies After Fibrinolytic Treatment in STEMI.
Topics: Clopidogrel; Fibrinolysis; Humans; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor | 2019 |
Improving the prehospital management of ST elevation myocardial infarction: a national quality improvement initiative.
Topics: Aspirin; Clopidogrel; Electrocardiography; Emergency Medical Services; Guideline Adherence; Humans; Nitroglycerin; Platelet Aggregation Inhibitors; Qatar; Quality Improvement; Quality Indicators, Health Care; ST Elevation Myocardial Infarction; Vasodilator Agents | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prognosis; Proportional Hazards Models; ST Elevation Myocardial Infarction; Stroke | 2019 |
In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience.
Topics: Aged; Clopidogrel; Female; Hospitalization; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tertiary Healthcare; Thrombosis; Ticlopidine | 2016 |
Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy.
Topics: Absorbable Implants; Adult; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Prosthesis Design; ST Elevation Myocardial Infarction; Ticlopidine; Tissue Scaffolds; Withholding Treatment | 2017 |
Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy.
Topics: Abciximab; Adenosine; Aged; Antibodies, Monoclonal; Catheterization, Peripheral; Clopidogrel; Female; Hematoma; Hemorrhage; Hemostatic Techniques; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Punctures; Purinergic P2Y Receptor Antagonists; Radial Artery; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
One-year incidence and clinical impact of bleeding events in patients treated with prasugrel or clopidogrel after ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors | 2016 |
[ST-segment elevation myocardial infarction in the eastern urban China: from 2001 to 2011].
Topics: Aged; Aspirin; China; Clopidogrel; Female; Hospitalization; Hospitals; Humans; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Registries; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Ticlopidine | 2016 |
Clopidogrel loading dose in the management of ST elevation myocardial infarction: Still a debate!
Topics: Clopidogrel; Guideline Adherence; Humans; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticlopidine | 2016 |
Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Patient Transfer; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; ST Elevation Myocardial Infarction; Ticlopidine; Time Factors; Time-to-Treatment; Treatment Outcome; Troponin T | 2016 |
Prehospital Clopidogrel Administration in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary PCI: Real-Life Experience From the Multicenter NRDES Registry.
Topics: Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; ST Elevation Myocardial Infarction; Ticlopidine | 2016 |
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Survival Analysis; Ticagrelor; Ticlopidine | 2016 |
The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticlopidine | 2016 |
Left ventricular non-compaction cardiomyopathy: Incidental diagnosis after ST-elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiomyopathy, Hypertrophic, Familial; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Echocardiography, Doppler, Color; Electrocardiography; Female; Hematologic Agents; Humans; Incidental Findings; ST Elevation Myocardial Infarction; Thrombosis; Ticlopidine; Treatment Outcome; Warfarin | 2016 |
In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
Topics: Adenosine; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical Services; Emergency Service, Hospital; Female; Hemorrhage; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Young Adult | 2016 |
Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome.
Topics: Aged; Belgium; Clopidogrel; Female; Hospitalization; Humans; Italy; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Retrospective Studies; Smoking; ST Elevation Myocardial Infarction; Ticlopidine | 2017 |
Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; C-Reactive Protein; Chi-Square Distribution; Clopidogrel; Echocardiography; Female; Humans; Inflammation Mediators; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ST Elevation Myocardial Infarction; Stents; Ticlopidine; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Pulmonary alveolar hemorrhage mimicking a pneumopathy: a rare complication of dual antiplatelet therapy for ST elevation myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Lung Diseases; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pulmonary Alveoli; ST Elevation Myocardial Infarction; Ticlopidine; Tomography, X-Ray Computed | 2016 |
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; International Cooperation; Long Term Adverse Effects; Male; Middle Aged; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; ST Elevation Myocardial Infarction; Ticlopidine | 2017 |